Infliximab enhances the therapeutic effectiveness of octreotide on acute necrotizing pancreatitis in rat model

Pancreas

Volumn 41, Issue 6, 2012, Pages 849-854

  Huang, Yao Xing ^a   Li, Wei Dong ^a   Jia, Lin ^a   Qiu, Jia Hua ^a   Jiang, Shu Man ^a   Ou, Ya ^a   Du, Hong ^a  

^a GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

acute necrosis pancreatitis; infliximab; octreotide; tumor necrosis factor

Indexed keywords

AMINE OXIDASE (COPPER CONTAINING); INFLIXIMAB; OCTREOTIDE; TAUROCHOLIC ACID; TRYPSIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEMORRHAGIC PANCREATITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; BLOOD OXYGEN TENSION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG POTENTIATION; FEMALE; INCIDENCE; KIDNEY DYSFUNCTION; KIDNEY PARENCHYMA; LIVER; LIVER DYSFUNCTION; LUNG PARENCHYMA; MULTIPLE ORGAN FAILURE; NONHUMAN; PANCREAS; PRIORITY JOURNAL; RAT; RESPIRATORY FAILURE;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; INJECTIONS, INTRAVENOUS; LIVER FAILURE; MULTIPLE ORGAN FAILURE; OCTREOTIDE; PANCREATITIS, ACUTE NECROTIZING; PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; RENAL INSUFFICIENCY; RESPIRATORY INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; TAUROCHOLIC ACID; TIME FACTORS;

EID: 84863942532     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31823fbdc3     Document Type: Article

References (25)

1. Bhatia M. Acute pancreatitis as a model of SIRS. Front Biosci. 2009;1:2042Y2050.
2. Duell EJ, Casella DP, Burk RD, et al. Inflammation, genetic polymorphisms in proinflammatory genes TNFALPHA, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15:726Y731.
3. Triantafillidis JK, Cheracakis P, Hereti IA, et al. Acute idiopathic pancreatitis complicating active Crohn's disease: favorable response to infliximab treatment. Am J Gastroenterol. 2000;95:3334Y3336.
4. Silbermintz A, Krishnan S, Banquet A, et al. Granulomatous pneumonitis, sclerosing cholangitis, and pancreatitis in a child with Crohn disease: response to infliximab. J Pediatr Gastroenterol Nutr. 2006;42:324Y326.
5. Zhang XP, Zhang L, Yang P, et al. Protective effects of baicalin and octreotide on multiple organ injury in severe acute pancreatitis. Dig Dis Sci. 2008;53:581Y591.
6. Aho HJ, Nevalainen TJ, Lindberg RL, et al. Experimental pancreatitis in the rat. The role of phospholipase A in sodium taurocholate-induced acute haemorrhagic pancreatitis. Scand J Gastroenterol. 1980;15: 1027Y1031.
7. Jha RK, Yong MQ, Chen SH. The protective effect of resveratrol on the intestinal mucosal barrier in rats with severe acute pancreatitis. Med Sci Monit. 2008;14:BR14YBR19.
8. Zhang XP, Chen L, Hu QF, et al. Effects of large dose of dexamethasone on inflammatory mediators and pancreatic cell apoptosis of rats with severe acute pancreatitis. World J Gastroenterol. 2007;13:5506Y5511.
9. Avni B, Haddad R, Kashtan H, et al. Octreotide ameliorates glucose intolerance following acute experimental pancreatitis. Dig Dis Sci. 1998;43:193Y202.
10. Redlich K, Hayer S, Maier A, et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. 2002;46:785Y792.
11. Schmidt J, Rattner DW, Lewandrowski K, et al. A better model of acute pancreatitis for evaluating therapy. Ann Surg. 1992;215:44Y56.
12. Paller MS, Hoidal JR, Ferris TF. Oxygen free radicals in ischemic acute renal failure in the rat. J Clin Invest. 1984;74(4):1156Y1164.
13. Fan JG, Xu ZJ, Wang GL. Effect of lactulose on establishment of a rat non-alcoholic steatohepatitis model. World J Gastroenterol. 2005;11:5053Y5056.
14. Mikawa K, Nishina K, Takao Y, et al. ONO-1714, a nitric oxide synthase inhibitor, attenuates endotoxin-induced acute lung injury in rabbits. AnesthAnalg. 2003;97(6):1751Y1755.
15. Hu S, Sheng Z, Zhou B, et al. Study on delay two-phase multiple organ dysfunction syndrome. Chin Med J. 1998;111:101Y108.
16. Harper SJ, Cheslyn-Curtis S. Acute pancreatitis. Ann Clin Biochem. 2011;48:23Y37.
17. Andris A. Pancreatitis: understanding the disease and implications for care. AACN Adv Crit Care. 2010;21:195Y204.
18. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907Y916.
19. Knight DM, Trinh H, Le J. Construction and initial characterization of mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993;30:1443Y1453.
20. Keystone EC, Ware CF. Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis. Rheum Dis Clin N Am. 2001;27: 427Y443.
21. Fefferman DS, Alsahli M, Lodhavia PJ, et al. Re: Triantafillidis et al.VAcute idiopathic pancreatitis complicating active Crohn's disease: favorable response to infliximab treatment. Am J Gastroenterol. 2001;96:2510Y2511.
22. Sleisinger MH, Fordtran JS. Gastrointestinal and liver, disease, pathophysiology, diagnosis, management. 6th ed. Philadelphia, PA: WB Saunders Company. 2010:959Y983.
23. Ammori BJ, Becker KL, Kite P, et al. Calcitonin precursors: early markers of gut barrier dysfunction in patients with acute pancreatitis. Pancreas. 2003;27:239Y243.
24. Rychter JW, van Minnen LP, Verheem A. Pretreatment but not treatment with probiotics abolishes mouse intestinal barrier dysfunction in acute pancreatitis. Surgery. 2009;145(2):157Y167.
25. Oruc N, Ozutemiz AO, Yukselen V, et al. Infliximab: a new therapeutic agent in acute pancreatitis? Pancreas. 2004;28:1Y8.